Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 6/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | CNR1 | P21554 | 1/20 | 0.57 |
| ▸ | CNR2 | P34972 | 1/20 | 0.57 |
| ▸ | DRD4 | P21917 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12228161 | 0.87 | BCHE (0.72) | BCHECYP2D6DRD4DRD2ADRA1D | |
| SCHEMBL10650029 | 0.87 | CYP2D6 (0.67) | BCHECYP2D6KCNH2KDM4EMAPK1 | |
| SCHEMBL3834709 | 0.87 | BCHE (0.70) | BCHEDRD4KDM4E | |
| SCHEMBL5947165 | 0.87 | KMT2A (0.60) | BCHECYP2D6KCNH2 | |
| SCHEMBL19532617 | 0.84 | BCHE (0.71) | BCHECYP2D6KCNH2CNR1CNR2 | |
| SCHEMBL5947378 | 0.84 | BCHE (0.65) | BCHECYP2D6DRD4DRD2ADRA1D | |
| SCHEMBL5947547 | 0.83 | BCHE (0.59) | BCHECYP2D6KCNH2KDM4EMAPK1 | |
| SCHEMBL14197926 | 0.83 | BCHE (0.67) | BCHECYP2D6CNR1CNR2DRD4 | |
| SCHEMBL14051120 | 0.83 | CYP2D6 (0.56) | CYP2D6KCNH2PPARG | |
| SCHEMBL3957976 | 0.82 | BCHE (0.78) | BCHEDRD4DRD2ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150065490-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| EP-1529038-B1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2009-10-07 | — | — | EP | disclosed |
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | CUENOUD BERNARD | 2007-10-25 | — | — | US | disclosed |
| CN-1301980-C | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | NOVARTIS AG (CH) | 2007-02-28 | — | — | CN | disclosed |
| US-20060106075-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | NOVARTIS AG (CH) | 2006-05-18 | — | — | US | disclosed |
| CN-1701064-A | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | NOVARTIS AG (CH) | 2005-11-23 | — | — | CN | disclosed |
| EP-1529038-A1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | Novartis AG (CH) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004016601-A1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | BCHE 2672/4885CYP2D6 1199/4885KCNH2 418/4885 |
| US-20060106075-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | BCHE 2672/4885CYP2D6 1199/4885KCNH2 418/4885 |
| US-20150065490-A1 | ORGANIC COMPOUNDS | ADRB2, ADRA2C, ADRB1 | BCHE 3245/4885CYP2D6 148/4885KCNH2 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.